

TABLE OF CONTENTS

PART I: INTRODUCTION: PEDAGOGY, GUIDELINES AND INSTRUCTION FOR USE OF THIS CURRICULUM

PEDAGOGY, GUIDELINES AND INSTRUCTIONS FOR USE	6
Background, Objectives, and Rationale.....	6
Use of Lecture Modules.....	8
Getting Help.....	8
OVERVIEW AND EDUCATIONAL OBJECTIVES	9
Knowledge	9
Skills	9
TIPS ON CONTENT AND PEDAGOGY	10
Special Considerations Related to Lectures.....	11
ACKNOWLEDGEMENTS	12
CONTRIBUTORS	12

PART II: TEACHING AND PEDAGOGY FOR MEDICAL STUDENT PROGRAMS

PREFACE	14
RATIONALE.....	14
ORGANIZATION OF A PSYCHOPHARMACOLOGY PROGRAM WITHIN A MEDICAL STUDENT PROGRAM.....	16
OVERVIEW AND EDUCATIONAL OBJECTIVES	17
Knowledge	17
Skills	17
TIPS ON CONTENT AND PEDAGOGY	18
Special Considerations Related to Lectures.....	19
Issues, Concepts, and a Template	20
Material on Psychosocial Topics	23
Supervision	25
Reading Materials	25
DOING AN EVALUATION	26

APPENDICES

APPENDIX A: Excerpted from ADMSEP Clinical Learning Objectives Psychiatry Education of Medical Students (Introduction on Psychopharmacology)	27
APPENDIX B: Outline of The Stanford Psychiatry Core Clerkship Objectives	34

APPENDIX C: Overview Articles on Psychopharmacology Practice	39
Special Considerations Related to Lectures.....	40
Carl “Salzman’s 7 Sins of Psychopharmacology”	47
APPENDIX D: Reading Materials	49
APPENDIX E: Computers and Psychopharmacology.....	54

PART III: LECTURES

CORE LECTURES – AUTHORS (COMMITTEE REVIEWERS)

<u>Basic Psychopharmacology</u>	1.1 – 1.63
Mujeeb U. Shad, M.D. (Daniel G. Orr, M.D.)	
<u>Making A Diagnosis Before Treatment</u>	2.1 – 2.65
David V. Sheehan, M.D., M.B.A (Richard Balon, M.D.)	
<u>Anxiety Disorders: OCD</u>	3.1 – 3.38
Robert H. Howland, M.D. (Matthew Macaluso, D.O.)	
<u>GAD & PTSD/Social Anxiety/Phobias/Panic Disorder</u>	4.1 – 4.39
Robert H. Howland, M.D. (Matthew Macaluso, D.O.)	
<u>Depression</u>	5.1 – 5.96
Daniel G. Orr, M.D. (Marvin Leifer, M.D.)	
<u>Bipolar Disorder</u>	6.1 – 6.42
Po Wang, M.D. (Ira D. Glick, M.D.)	
<u>Treatment of Schizophrenia</u>	7.1 – 7.61
Michael Jibson, M.D., Ph.D, Ira D. Glick, M.D.	
<u>Personality Disorders</u>	8.1 – 8.75
Donald W. Black, M.D., Larry J. Siever, M.D., Mujeeb Shad, M.D., M.S.C.S. (Justin Faden, D.O.)	
<u>ADHD: Child/Adolescent/Adult</u>	9.1 – 9.72
Daniel G. Orr, M.D. (Jeffrey Newcorn, M.D., Edgar Hernandez, M.D.)	
<u>Eating Disorders</u>	10.1 – 10.52
Kimberly Rosania, Ph.D., Jennifer Derenne, M.D., James Lock, M.D., Ph.D. (Saeed Ahmed,	

M.D.)	
<u>Substance Use Disorders: Overview</u>	11.1 – 11.66
Po Wang, M.D. (Mujeeb Shad, M.D.)	
<u>Insomnia/Sleep Disorders</u>	12.1 – 12.62
Rafael Pelayo, M.D., Lawrence Adler M.D. (Lawrence Cohen, Pharm. D.)	
<u>Womens Wellness: Pregnancy/Breastfeeding</u>	13.1 – 13.39
Katherine E. Williams, M.D. (Matej Markota, M.D.)	
<u>Basic Child and Adolescent Psychopharmacology</u>	14.1 – 14.24
Glen R. Elliott, Ph.D., M.D. (Lawrence Adler, M.D.)	
<u>Geriatric Psychopharmacology</u>	15.1 – 15.33
Lawrence Adler, M.D., Linda Farho, Pharm. D. (Robert Howland, M.D.)	
<u>Managing Neurocognitive Behavioral Symptoms in Patients with Major Neurocognitive Disorders</u>	16.1 – 16.44
James Ellison, M.D., Ira D. Glick, M.D.	
<u>Evaluating and Managing Side Effects of Psychiatric Medications</u>	17.1 – 17.41
Joseph F. Goldberg, M.D., Robert H. Howland, M.D. (Marvin Leifer, M.D.)	
<u>Psychopharmacology Warnings and Management</u>	18.1 – 18.62
Daniel G. Orr, M.D. (Thomas Raedler, M.D.)	
<u>Psychogenomics</u>	19.1 – 19.30
John F. Greden, M.D. (Tiffany Schwasinger-Schmidt, M.D. Ph.D., Daniel G. Orr, M.D.)	
<u>The Art of Psychopharmacology</u>	20.1 – 20.21
Ira. D. Glick, M.D., Richard Balon, M.D. (Robert H. Howland, M.D.)	

AN OPTIONAL COURSE ON SUBSTANCE ABUSE

For medical student and primary care physician educators, these lectures have been reviewed and updated by Professor Charles P. O’Brien. He notes that the biggest news is the opioid epidemic. This was influenced by the concern about not neglecting pain as an important symptom. We started teaching doctors about the safety and benefits of prescription opioids. At least on pharma company aggressively (“allegedly”) marketed their product as having low addiction risk. Medical students and residents received very little training on the proper way to prescribe opioids and how to treat pain in a multi-disciplinary program. Also, supplies of opioids leaked out to the street market. Not only did the abuse of opioids increase, but it fueled heroin use which was usually cheaper than prescription opioids.

Students should be taught the risks and benefits of opioids, the non-opioid methods to treat pain, the opioid addiction medications in combination with counseling/psychotherapy. Important medications include methadone, buprenorphine (Suboxone), naltrexone and extended release naltrexone (Vivitrol) and naloxone (Narcan) for overdose.

We have summarized the entire course in two lectures, reviewed and compiled by Mujeeb Shad, M.D. Teachers may use the two lectures OR the entire 14 lecture series.

Summary Lectures

Psychopharmacology of Addiction.....21.1 – 21.64
Charles P. O'Brien, M.D., Ph.D., Mujeeb Shad, M.D.

Neurobiology Addictions: Part I and II22.1 – 22.111
Charles P. O'Brien, M.D., Ph.D., Mujeeb Shad, M.D.

Full Course Lectures

Addiction: A Disease of the Brain.....23.1 – 23.49
Charles P. O'Brien, M.D., Ph.D.

Substance Abuse: The Nation's Number One Health Problem24.1 – 24.31
James Cornish, M.D.

Cannabis.....25.1 – 25.45
Charles P. O'Brien, M.D., Ph.D., John T. Pichot, M.D.

Hallucinogens26.1 – 26.54
Benoit Dubé, M.D.

Prescription Drug Abuse.....27.1 – 27.44
Kyle M. Kampman, M.D.

Psychiatric Disorders and Psychotherapy of Substance Abuse28.1 – 28.51
Robert M. Weinrieb, M.D.

Effects of Drugs on the Developing Brain: Pregnancy, Adolescence and Beyond29.1 – 29.40
Marina Goldman, M.D.

Medical Complications of Substance Abuse30.1 – 30.105
Phil Green, M.D.

Genetics of Substance Abuse and Neuropharmacology of Opiates.....31.1 – 31.57
Wade Berrettini, M.D.

Genetics of Addiction.....32.1 – 32.50
Wade Berrettini, M.D.

<u>Neurobiology of Addiction</u>	33.1 – 33.40
Charles P. O’Brien, M.D., Ph.D.	
<u>Cocaine and Stimulants</u>	34.1 – 34.42
Kyle M. Kampman, M.D.	
<u>Nicotine Dependence</u>	35.1 – 35.45
Henry R. Kranzler, M.D.	
<u>Alcohol Dependence</u>	36.1 – 36.56
Henry R. Kranzler, M.D.	